Brief: Merck Announces TroFuse-005 Trial Evaluating Sacituzumab Tirumotecan Met Primary Endpoints Of Overall Survival And Progression-Free Survival In Certain Patients With Advanced Or Recurrent Endometrial Cancer

Merck & Co

18/05/2026 11:48

May 18 (Reuters) - Merck & Co Inc MRK.N:

MERCK ANNOUNCES TROFUSE-005 TRIAL EVALUATING SACITUZUMAB TIRUMOTECAN (SAC-TMT) MET PRIMARY ENDPOINTS OF OVERALL SURVIVAL (OS) AND PROGRESSION-FREE SURVIVAL (PFS) IN CERTAIN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER

MERCK  CO INC: SAFETY PROFILE WAS CONSISTENT WITH WHAT HAS BEEN OBSERVED IN PREVIOUSLY REPORTED STUDIES OF SAC-TMT

MERCK: SAC-TMT SHOWED STATISTICALLY SIGNIFICANT  CLINICALLY MEANINGFUL IMPROVEMENT IN OS AND PFS COMPARED TO TREATMENT OF PHYSICIAN'S CHOICE

MERCK  CO INC: STUDY ALSO REACHED ITS KEY SECONDARY ENDPOINT OF OBJECTIVE RESPONSE RATE

Source text: ID:nBw1w2mVWa

Further company coverage: MRK.N

 ((Reuters.Briefs@thomsonreuters.com;))